Northwest Biotherapeutics, Inc. (NWBO)
USD 0.27
(1.89%)
USD 0.27
(1.89%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 45.56 Million USD | 73.54% |
| 2022 | 26.25 Million USD | -30.8% |
| 2021 | 37.93 Million USD | 91.06% |
| 2020 | 19.85 Million USD | 10.12% |
| 2019 | 18.03 Million USD | 7.35% |
| 2018 | 16.79 Million USD | -46.56% |
| 2017 | 31.42 Million USD | 0.83% |
| 2016 | 31.17 Million USD | 43.38% |
| 2015 | 21.74 Million USD | -15.28% |
| 2014 | 25.66 Million USD | 2000.0% |
| 2013 | 1.22 Million USD | -68.44% |
| 2012 | 3.87 Million USD | -74.62% |
| 2011 | 15.25 Million USD | 53.29% |
| 2010 | 9.95 Million USD | 24.29% |
| 2009 | 8 Million USD | 6.77% |
| 2008 | 7.5 Million USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 2.5 Million USD | -62.59% |
| 2005 | 6.69 Million USD | 104.4% |
| 2004 | 3.27 Million USD | 2326.67% |
| 2003 | 135 Thousand USD | -77.16% |
| 2002 | 591 Thousand USD | 213.24% |
| 2001 | 188.67 Thousand USD | -95.97% |
| 2000 | 4.68 Million USD | 60.91% |
| 1999 | 2.91 Million USD | 0.0% |
| 1998 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 49.07 Million USD | 7.72% |
| 2024 Q2 | 55.57 Million USD | 13.24% |
| 2023 Q1 | 31.36 Million USD | 19.47% |
| 2023 Q3 | 37.44 Million USD | 21.72% |
| 2023 Q2 | 30.75 Million USD | -1.93% |
| 2023 Q4 | 45.56 Million USD | 21.69% |
| 2023 FY | 45.56 Million USD | 73.54% |
| 2022 Q4 | 26.25 Million USD | -14.14% |
| 2022 Q3 | 30.57 Million USD | -2.48% |
| 2022 Q1 | 33.61 Million USD | -11.4% |
| 2022 FY | 26.25 Million USD | -30.8% |
| 2022 Q2 | 31.35 Million USD | -6.73% |
| 2021 FY | 37.93 Million USD | 91.06% |
| 2021 Q1 | 24.79 Million USD | 24.87% |
| 2021 Q3 | 26.01 Million USD | 0.8% |
| 2021 Q2 | 25.8 Million USD | 4.07% |
| 2021 Q4 | 37.93 Million USD | 45.85% |
| 2020 Q4 | 19.85 Million USD | -16.47% |
| 2020 FY | 19.85 Million USD | 10.12% |
| 2020 Q3 | 23.77 Million USD | 14.05% |
| 2020 Q2 | 20.84 Million USD | 21.07% |
| 2020 Q1 | 17.21 Million USD | -4.53% |
| 2019 Q2 | 21.12 Million USD | -8.41% |
| 2019 Q1 | 23.06 Million USD | 37.32% |
| 2019 FY | 18.03 Million USD | 7.35% |
| 2019 Q4 | 18.03 Million USD | -2.8% |
| 2019 Q3 | 18.55 Million USD | -12.19% |
| 2018 Q4 | 16.79 Million USD | -47.3% |
| 2018 FY | 16.79 Million USD | -46.56% |
| 2018 Q1 | 31.72 Million USD | 0.95% |
| 2018 Q2 | 32.79 Million USD | 3.35% |
| 2018 Q3 | 31.87 Million USD | -2.8% |
| 2017 Q2 | 32.02 Million USD | -3.72% |
| 2017 Q1 | 33.26 Million USD | 6.72% |
| 2017 FY | 31.42 Million USD | 0.83% |
| 2017 Q4 | 31.42 Million USD | 16.4% |
| 2017 Q3 | 27 Million USD | -15.69% |
| 2016 Q2 | 21.35 Million USD | -2.8% |
| 2016 Q1 | 21.97 Million USD | 1.08% |
| 2016 Q3 | 20.6 Million USD | -3.53% |
| 2016 FY | 31.17 Million USD | 43.38% |
| 2016 Q4 | 31.17 Million USD | 51.29% |
| 2015 Q1 | 30.16 Million USD | 17.56% |
| 2015 Q3 | 21.62 Million USD | -7.72% |
| 2015 Q2 | 23.43 Million USD | -22.31% |
| 2015 Q4 | 21.74 Million USD | 0.51% |
| 2015 FY | 21.74 Million USD | -15.28% |
| 2014 Q4 | 25.66 Million USD | 51.95% |
| 2014 Q3 | 16.88 Million USD | 1341.04% |
| 2014 Q2 | 1.17 Million USD | 0.0% |
| 2014 Q1 | 1.17 Million USD | -4.09% |
| 2014 FY | 25.66 Million USD | 2000.0% |
| 2013 FY | 1.22 Million USD | -68.44% |
| 2013 Q3 | 1.6 Million USD | -29.69% |
| 2013 Q1 | 3.41 Million USD | -11.75% |
| 2013 Q2 | 2.27 Million USD | -33.36% |
| 2013 Q4 | 1.22 Million USD | -23.67% |
| 2012 Q4 | 3.87 Million USD | -82.52% |
| 2012 Q2 | 20.29 Million USD | 23.64% |
| 2012 FY | 3.87 Million USD | -74.62% |
| 2012 Q1 | 16.41 Million USD | 7.56% |
| 2012 Q3 | 22.15 Million USD | 9.19% |
| 2011 Q1 | 11.11 Million USD | 11.7% |
| 2011 FY | 15.25 Million USD | 53.29% |
| 2011 Q4 | 15.25 Million USD | 24.52% |
| 2011 Q3 | 12.25 Million USD | 1.46% |
| 2011 Q2 | 12.07 Million USD | 8.62% |
| 2010 Q1 | 8.64 Million USD | 7.98% |
| 2010 Q2 | 8.02 Million USD | -7.19% |
| 2010 Q3 | 10.12 Million USD | 26.16% |
| 2010 Q4 | 9.95 Million USD | -1.7% |
| 2010 FY | 9.95 Million USD | 24.29% |
| 2009 Q4 | 8 Million USD | 6.69% |
| 2009 FY | 8 Million USD | 6.77% |
| 2009 Q2 | 8.84 Million USD | 1.72% |
| 2009 Q3 | 7.5 Million USD | -15.14% |
| 2009 Q1 | 8.69 Million USD | 15.93% |
| 2008 Q2 | 4.06 Million USD | 0.0% |
| 2008 FY | 7.5 Million USD | 0.0% |
| 2008 Q4 | 7.5 Million USD | 43.92% |
| 2008 Q3 | 5.21 Million USD | 28.09% |
| 2008 Q1 | - USD | 0.0% |
| 2007 FY | - USD | -100.0% |
| 2007 Q1 | 3.63 Million USD | 45.11% |
| 2007 Q2 | 5.11 Million USD | 40.83% |
| 2007 Q3 | 5.24 Million USD | 2.42% |
| 2007 Q4 | - USD | -100.0% |
| 2006 Q2 | 521 Thousand USD | -93.19% |
| 2006 Q3 | 784 Thousand USD | 50.48% |
| 2006 Q4 | 2.5 Million USD | 219.52% |
| 2006 FY | 2.5 Million USD | -62.59% |
| 2006 Q1 | 7.64 Million USD | 14.23% |
| 2005 FY | 6.69 Million USD | 104.4% |
| 2005 Q1 | 4.01 Million USD | 22.62% |
| 2005 Q4 | 6.69 Million USD | 15.95% |
| 2005 Q2 | 4.88 Million USD | 21.71% |
| 2005 Q3 | 5.77 Million USD | 18.12% |
| 2004 FY | 3.27 Million USD | 2326.67% |
| 2004 Q4 | 3.27 Million USD | 75.66% |
| 2004 Q3 | 1.86 Million USD | 358.23% |
| 2004 Q1 | 227 Thousand USD | 68.15% |
| 2004 Q2 | 407 Thousand USD | 79.3% |
| 2003 Q4 | 135 Thousand USD | 26.17% |
| 2003 Q2 | 226 Thousand USD | -45.41% |
| 2003 Q3 | 107 Thousand USD | -52.65% |
| 2003 Q1 | 414 Thousand USD | -29.95% |
| 2003 FY | 135 Thousand USD | -77.16% |
| 2002 Q1 | 172.85 Thousand USD | -8.38% |
| 2002 Q2 | 213.99 Thousand USD | 23.8% |
| 2002 Q3 | 190 Thousand USD | -11.21% |
| 2002 Q4 | 591 Thousand USD | 211.05% |
| 2002 FY | 591 Thousand USD | 213.24% |
| 2001 Q4 | 188.67 Thousand USD | -94.25% |
| 2001 FY | 188.67 Thousand USD | -95.97% |
| 2001 Q1 | 844.07 Million USD | 0.0% |
| 2001 Q3 | 3.28 Million USD | 0.61% |
| 2001 Q2 | 3.26 Million USD | -99.61% |
| 2000 FY | 4.68 Million USD | 60.91% |
| 1999 FY | 2.91 Million USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -10.574% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -1005.3% |
| SQZ Biotechnologies Company | 27.47 Million USD | -65.848% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -5.042% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -53.055% |
| Mesoblast Limited | 118.7 Million USD | 61.618% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -4704.534% |
| Genus plc | 233.1 Million USD | 80.455% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -1454.743% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -3290.931% |
| Marizyme, Inc. | 18.71 Million USD | -143.409% |
| ContraFect Corporation | 2.88 Million USD | -1481.395% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -5974.667% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -33526.842% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -3050.066% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -1858.765% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -705.181% |
| MultiCell Technologies, Inc. | 202.58 USD | -22489780.541% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 20.75% |
| EV Biologics, Inc. | 1.49 Million USD | -2947.999% |
| Q BioMed Inc. | 4.1 Million USD | -1008.521% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -37.639% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -7130.862% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -3609.007% |
| Biomind Labs Inc. | 735.54 Thousand USD | -6094.072% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 73.441% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -250.543% |
| Skye Bioscience, Inc. | 4.61 Million USD | -887.159% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -5030.261% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -32093.785% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -676.006% |
| IMV Inc. | 28.88 Million USD | -57.735% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -177045.301% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -1917.374% |
| GB Sciences, Inc. | 1.75 Million USD | -2489.656% |
| Alpha Cognition Inc. | 1.22 Million USD | -3633.288% |
| HST Global, Inc. | 98.31 Thousand USD | -46238.958% |
| CSL Limited | 12.18 Billion USD | 99.626% |
| Halberd Corporation | 150 Thousand USD | -30273.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -4472.745% |
| Resverlogix Corp. | 6.49 Million USD | -601.895% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -9441.361% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -17725.284% |
| argenx SE | 20 Million USD | -127.8% |
| MetaStat, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1581.986% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -445474.572% |
| Genscript Biotech Corporation | 417.73 Million USD | 89.094% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -22610.053% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -1800.135% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -19769.947% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 32.646% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -1405.523% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -12565.759% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -124.124% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -30548.351% |
| BioStem Technologies, Inc. | 4.71 Million USD | -867.013% |
| ONE Bio Corp. | 19.71 Million USD | -131.093% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -18110.743% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -18217.787% |
| Agentix Corp. | 50 Thousand USD | -91020.0% |
| LadRx Corporation | 33.6 Thousand USD | -135471.029% |
| Cell Source, Inc. | 9.25 Million USD | -392.318% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -5924.829% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -5924.829% |
| NovAccess Global Inc. | 2.19 Million USD | -1971.022% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -544.157% |
| Itoco Inc. | 228.37 Thousand USD | -19849.47% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -21494.976% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -814.309% |
| Kadimastem Ltd | 891.22 Thousand USD | -5012.059% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -11237.592% |
| CytoDyn Inc. | 30.07 Million USD | -51.483% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -9307.703% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -12848.81% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -482.612% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -37091.837% |
| Rebus Holdings, Inc. | 310 Thousand USD | -14596.774% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -862.139% |
| International Stem Cell Corporation | 4.17 Million USD | -990.474% |
| Bioxytran, Inc. | 1.92 Million USD | -2266.753% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -72897.613% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1989.046% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -447.86% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -430.693% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -2829.001% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -16900.0% |
| Neutra Corp. | 54.15 Thousand USD | -84027.336% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -2389.617% |
| PureTech Health plc | 25.51 Million USD | -78.583% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -3621.535% |
| IXICO plc | 472.02 Thousand USD | -9552.072% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -193.917% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 26.827% |
| CSL Limited | 12.18 Billion USD | 99.626% |
| Cellectis S.A. | 92.77 Million USD | 50.893% |